News
-
Thursday 5th May 2016
Leeds takes part in world-wide lupus trial
Recruitment is due to start at NIHR Leeds CRF on a world-wide trial looking at the effectiveness of a new treatment for a potentially serious kidney condition, called lupus nephritis (LN), caused by prolonged inflammation of the kidneys. The trial, sponsored by AstraZeneca, will look at the use of a monoclonal antibody, called anifrolumab, which is thought to prevent progression of...
Read more
-
Wednesday 4th May 2016
Stage set for public engagement project
Research into oral and dental health will take to the stage next month, as part of a public engagement project involving NIHR Leeds CRF researchers. The play – ‘Don’t Smile’ –...
Read more
-
Thursday 28th April 2016
New trial investigates non-response to rheumatoid arthritis treatment
A trial to uncover why around 40 per cent of patients suffering from rheumatoid arthritis do not respond to otherwise highly effective current drug therapies is being conducted by the...
Read more
-
Monday 4th April 2016
New trial finds vitamin D3 improves heart function
A daily dose of vitamin D3 improves heart function in people with chronic heart failure, a trial carried out at the NIHR Leeds Clinical Research Facility has found. The VINDICATE study...
Read more
-
Friday 18th March 2016
New use for anti-clotting agent to be trialled in Leeds
A new technique to improve the outcome of patients suffering a heart attack is being trialled at the NIHR Leeds Clinical Research Facility. The study, funded by the National Institute for...
Read more
-
Monday 15th February 2016
Cannabis-based drug in further trials
A drug assessed in a Phase 1 trial at NIHR Leeds CRF has now moved on to further trials in the USA and Europe. The drug, dexanabinol, is a synthetic cannabinoid...
Read more
-
Saturday 12th December 2015
New reovirus trials to begin in Leeds
NIHR Leeds CRF is working with Oncolytics Biotech on a number of trials to test the use of the oncolytic virus Reolysin in combination with other treatments. Reolysin is a variant...
Read more